source
- FDA approves Priovant's Lisraya (brepocitinib) for rare skin disease dermatomyositisThe U.S. Food and Drug Administration has cleared the first oral targeted treatment for dermatomyositis, a rare and disabling skin disorder. The medication, brepocitinib, will be sold under the br…
- Outer Bio unveils skin‑tissue platform that keeps samples alive for a month, creating terabytes of data for skincare researchOuter Bio, a new biotech founded by Michael Polansky, has emerged from stealth to offer a skin‑focused platform that maintains harvested human skin tissue alive for about a month. The company says…